Cargando…

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

Pioneering success of antibodies targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has changed the outlook of cancer therapy. Although these antibodies show impressive durable clinical activity, low response rates and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasikumar, Pottayil G., Ramachandra, Murali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108255/ https://www.ncbi.nlm.nih.gov/pubmed/35585982 http://dx.doi.org/10.3389/fimmu.2022.752065

Ejemplares similares

A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
por: Sasikumar, Pottayil, et al.
Publicado: (2013)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
por: Sasikumar, Pottayil G., et al.
Publicado: (2021)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
por: Mariotti, Francesca Romana, et al.
Publicado: (2019)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
por: Zhang, Weihao, et al.
Publicado: (2023)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
por: Feng, Chong, et al.
Publicado: (2023)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis
por: Bhattacharya, Debapriya, et al.
Publicado: (2014)

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
por: Schlicher, Lisa, et al.
Publicado: (2023)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Immune Checkpoint Molecules in Reproductive Immunology
por: Miko, Eva, et al.
Publicado: (2019)

Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer
por: Shevchenko, Ivan, et al.
Publicado: (2018)

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies
por: Morandi, Fabio, et al.
Publicado: (2022)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

The CD83 Molecule – An Important Immune Checkpoint
por: Grosche, Linda, et al.
Publicado: (2020)

Immune checkpoint molecules in prevention and development of asthma
por: Kanannejad, Zahra, et al.
Publicado: (2023)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy
por: Nüssing, Simone, et al.
Publicado: (2020)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

Targeting Immune Checkpoint Molecules to Eliminate Latent HIV
por: Boyer, Zoe, et al.
Publicado: (2018)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f2cg0mbgbegpf94hfis3ji9dtr